Project Details
Description
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 (200 mg BID) for 10 days
| Status | Finished |
|---|---|
| Effective start/end date | 6/17/14 → 12/31/15 |
Funding
- SUMMIT PLC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.